AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04704869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red Blood Cells
Description: RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study NCT04704869 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cells
Description: RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study NCT04704869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study NCT04704869 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma
Description: Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study NCT04704869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets
Description: Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study NCT04704869 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelets
Description: Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study NCT04704869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole Blood
Description: Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study NCT04704869 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood
Description: Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study NCT03049956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ocular vestibular evoced myogenic potentials
Description: The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
Study NCT03457025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
Study NCT03457025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Corticosteroids
Description: Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
Study NCT03457025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antivirals
Description: acyclovir 400mg: one pill 4 times daily for 7 days
Study NCT03457025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antivirals
Description: acyclovir 400mg: one pill 4 times daily for 7 days
Study NCT03457025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
Study NCT04482010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Local community-based HIV care
Description: Compared to the classic HIV care, community-based HIV care includes:~* Individual interviews with a psychosocial agent;~* Support groups conducted by psychosocial agents;~* Culinary workshops gathering PLWHIV and healthcare professionals;~* Home visits by a community worker;~* Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment.
Study NCT04146220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
Study NCT04146220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
Study NCT01513057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
Study NCT01513057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 250 mg capsules of Roche Laboratories Inc.
Study NCT02184494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
Description: Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration
Study NCT01783496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermage CPT
Description: Treatment with Thermage patterned, total, or framed tip
Study NCT01783496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermage CPT
Description: Treatment with Thermage patterned, total, or framed tip
Study NCT01691365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamins
Description: a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
Study NCT01691365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
Study NCT03840811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
Study NCT03840811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
Study NCT03840811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positie test of cure 1 week post initial antibiotic treatment
Study NCT03840811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA1090 A26
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
Study NCT03840811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA7537
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter
Study NCT00048971 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT00048971 — intervention group
Intervention type: GENETIC
Intervention: polymorphic microsatellite marker analysis
Study NCT01279642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Doppler vascular ultrasound guidance to PICC insertion in children -
Study NCT01279642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional puncture
Description: traditional approach of PICC insertion by visualization and inspection of insertion site
Study NCT01238822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 18 mg methylphenidate
Study NCT01238822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT01238822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 36 mg methylphenidate
Study NCT01238822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 54 mg methylphenidate
Study NCT01475669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (Human) (FCH)
Description: Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
Study NCT01475669 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
Study NCT01691755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral doses once a day for 26 weeks
Study NCT01691755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally once a day for 26 weeks
Study NCT03054025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Phone Monitoring Device
Description: Use activity tracker application
Study NCT02048397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Rehabilitation
Study NCT02048397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate
Study NCT01785875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
Study NCT04409002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
Study NCT04409002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study
Study NCT04409002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1
Study NCT02888132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum
Study NCT02888132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum
Study NCT03058497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature-Controlled Laminar Airflow Device (Airsonett®)
Study NCT03058497 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Temperature-Controlled Laminar Airflow Device (Airsonett®)
Study NCT00773526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5126766
Description: Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
Study NCT02974413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-care supported
Description: The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
Study NCT03780894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
Description: Administration of 2 mg of FC together with RBC and TXA
Study NCT03780894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cells concentrate
Description: Administration of 2 red blood cells concentrates together with FC and TXA
Study NCT03780894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Administration of 1g of TXA together with FC and RBC
Study NCT03780894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Administration of 1g of TXA together with FC and RBC
Study NCT00706706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate (SU011248)
Description: Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
Study NCT04273152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: advanced glycation endproducts reader
Description: advanced glycation endproducts reader
Study NCT03526107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CF Control
Description: CF Control: 587 mg of cocoa flavanols, \<1 mg caffeine and \<1 mg theobromine
Study NCT03526107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CF-Theobromine
Description: CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
Study NCT03526107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CF-Caffeine
Description: CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and \<1 mg theobromine
Study NCT00661674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
Study NCT03097757 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound - guided fracture reduction
Description: Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.
Study NCT03097757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care fracture reduction
Description: Closed reduction of a fractured bone.
Study NCT00661674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
Study NCT03097757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care fracture reduction
Description: Closed reduction of a fractured bone.
Study NCT01159808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: 3, 25 and 100 mg capsules; oral administration, single dose
Study NCT01159808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsules, oral administration, single dose
Study NCT04124211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: FMT will be performed through transendoscopic enteral tubing (TET) within one week during treatment period
Study NCT04126980 — intervention group
Intervention type: BEHAVIORAL
Intervention: Rates of readmission and reoperation
Description: All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.
Study NCT02572570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior
Description: Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Bulk Fill Posterior). Procedures done using local anesthesia and following ordinary restorative techniques.
Study NCT02572570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek Supreme Ultra
Description: Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Supreme Ultra). Procedures done using local anesthesia and following ordinary restorative techniques.
Study NCT04148586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation
Description: Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
Study NCT04148586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
Study NCT01215396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AminoVital Amino Acid formulation
Description: Contains minerals, vitamin C, flavour and sweetener.
Study NCT01215396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Vital Amino Acid formulation
Description: Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).
Study NCT01215396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Vital Amino Acid formulation
Description: Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
Study NCT03726970 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CBCT radiation
Description: CBCT scanning
Study NCT00442897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin (+) ezetimibe
Description: simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
Study NCT00442897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: atorvastatin
Description: atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
Study NCT01643577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture for gastroparesis
Description: A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
Study NCT01643577 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture for musculoskeletal pain
Description: Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
Study NCT04213885 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PXL 330 Platinum device/Riboflavin
Description: 30mW, 5 sec, 5 sec off, 10 minutes of illumination
Study NCT00661674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
Study NCT02881476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: Cell-based therapy
Description: Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
Study NCT04591418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotary handpieces
Description: Dental Caries removal
Study NCT04591418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Dental Caries removal
Study NCT01252628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866 (SCCHN)
Description: PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
Study NCT01252628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab (SCCHN)
Description: Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
Study NCT01252628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (SCCHN)
Description: Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
Study NCT01252628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866 (CRC)
Description: PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
Study NCT01252628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab (CRC)
Description: Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
Study NCT01252628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (CRC)
Description: Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.